WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center

Clearing 19 biologics for Europe market

Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types

The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials

China poised to launch world’s first CAR-T therapy for gastric cancer

As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies

RoosterBio taps MineBio to supercharge hMSC & exosome solutions in China

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial

Frontage Laboratories expands China presence with Teddy Lab acquisition

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer

Arctic Vision expands global reach with acquisition of MDCO Technology’s ophthalmic device business

AstraZeneca pledges $15 billion investment in China through 2030

UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."

Rapid-acting ADHD treatment Azstarys now approved in China

ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood